Lung cancer: Genetics of risk and advances in chemoprevention

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 4, 2005, Pages 265-271

  Keith, Robert L ^a   Miller, York E ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Chemoprevention; Genetic susceptibility; Lung cancer; Prostacyclin; Retinoids

Indexed keywords

BETA CAROTENE; BIOLOGICAL MARKER; CARCINOGEN; CELECOXIB; CORTICOSTEROID; CYCLIN DEPENDENT KINASE 2; GLUTATHIONE TRANSFERASE M1; HISTONE DEACETYLASE INHIBITOR; INOSITOL; ISOTHIOCYANIC ACID; ISOTRETINOIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SELENIUM DERIVATIVE;

CANCER RISK; CHEMOPROPHYLAXIS; DNA DAMAGE; DRUG HALF LIFE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETICS; HUMAN; LARYNX CANCER; LINKAGE ANALYSIS; LUNG CANCER; LUNG TUMOR; PHARYNX CANCER; PNEUMONIA; REVIEW;

EID: 23044434882     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000166493.77412.2d     Document Type: Review

References (71)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Lynch TJ, Adjei AA, Bunn PA Jr, et al. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004; 10:4199s-4204s. This article reviews new agents in cancer therapy, many of which are mechanistically targeted.
3. Tong L, Spitz MR, Fueger JJ, et al. Lung carcinoma in former smokers. Cancer 1996; 78:1004-1010.
4. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002; 8:314-346.
5. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35:1332-1338.
6. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
7. Kinsinger LS, Harris R, Woolf SH, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:59-69.
8. Bailey-Wilson JE, Amos Cl, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004; 75:460-474. This is a landmark article describing a major cooperative effort resulting in mapping a gene-determining susceptibility to lung cancer. Numerous follow-up publications will result from this effort. Before this, the existence of a major high-penetrance lung cancer susceptibility gene was doubted.
9. Tokukata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst 1963; 30:289-312.
10. Sellers TA, Bailey-Wilson JE, Elston RC, et al. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 1990; 82:1272-1279. [See comments.]
11. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 2004; 292:2977-2983. This important article describes the added risk for lung cancer of a positive family history.
12. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000; 9:3-28.
13. Stucker I, de WI, Cenee S, et al. GSTM1, smoking and lung cancer: a case-control study. Int J Epidemiol 1999; 28:829-835.
14. Qingyi W, Lie C, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-1772. [In-process citation.]
15. Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18:14-20.
16. Lerman C, Caporaso NE, Bush A, et al. Tryptophan hydroxylase gene variant and smoking behavior. Am J Med Genet 2001; 105:518-520.
17. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95:470-478.
18. Cohen BH, Diamond EL, Graves CG, et al. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 1977; 2:523-526.
19. Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987; 106:512-518.
20. Islam SS, Schottenfeld D. Declining FEV1 and chronic productive cough in cigarette smokers: a 25-year prospective study of lung cancer incidence in Tecumseh, Michigan. Cancer Epidemiol Biomarkers Prev 1994; 3:289-298.
21. Papi A, Casoni G, Caramori G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004; 59:679-681.
22. Kennedy TC, Proudfoot SP, Franklin WA, et al. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996; 56:4673-4678.
23. Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003; 12:987-993.
24. Omenn GS. Chemoprevention of lung cancer is proving difficult and frustrating, requiring new approaches. J Natl Cancer Inst 2000; 92:959-960.
25. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233-239. This is the first randomized trial to demonstrate efficacy of smoking cessation programs. Interestingly, in this group of smokers with mild to moderate airflow obstruction, lung cancer was the leading cause of death, surpassing cardiovascular disease.
26. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. This is one of two landmark papers describing the correlation of EGFR mutations and clinical response to EGFR tyrosine kinase inhibitors.
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139. This is one of two landmark papers describing the correlation of EGFR mutations and clinical response to EGFR tyrosine kinase inhibitors.
28. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003; 41(suppl 1):S29-S42.
29. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996; 2:1787-1793.
30. Malkinson AM. Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer 2001; 32:265-279.
31. Witschi H, Espiritu I, Dance ST, et al. A mouse lung tumor model of tobacco smoke carcinogenesis. Toxicol Sci 2002; 68:322-330.
32. Kwak I, Tsai SY, DeMayo FJ. Genetically engineered mouse models for lung cancer. Annu Rev Physiol 2004; 66:647-663. This is a useful review of a rapidly progressing area.
33. Malkinson AM. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 1998; 24:541-555.
34. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005; 37:48-55. This article documents application of gene expression profiling to develop a signature of tumors driven by ras mutation in mice and humans.
35. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4:181-189.
36. Wang Y, Zhang Z, Yan Y, et al. A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. Cancer Res 2004; 64:1647-1654. Although mouse models of adenocarcinoma are well established, no reproducible models of squamous cell lung cancer were available before this. Human chemoprevention trials now are focusing on intermediate end point biomarkers in the central airways. This model may be useful in preclinical evaluation of chemoprevention strategies before moving to intermediate end point trials.
37. Moody TW, Leyton J, Zakowicz H, et al. Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res 2001; 21:1749-1755.
38. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000; 21:179-182.
39. Gunning WT, Kramer PM, Lubet RA, et al. Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyl transferase inhibitor R115777. Clin Cancer Res 2003; 9:1927-1930.
40. Witschi H, Espiritu I, Uyeminami D. Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis 1999; 20:1375-1378.
41. El Bayoumy K, Upadhyaya P, Desai DH, et al. Effects of 1,4-phenylenebis (methylene)selenocyanate, phenethyl isothiocyanate, indole-3-carbinol, and d-limonene individually and in combination on the tumorigenicity of the tobacco-specific nitrosamine 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Anticancer Res 1996; 16:2709-2712.
42. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63:7089-7093.
43. Mian TA, Theiss JC, Gesell TF. Effect of vitamin A on lung tumorigenesis in irradiated and unirradiated strain A mice. Cancer Lett 1984; 22:103-112.
44. Frasca JM, Garfinkel L. 13-cis Retinoic acid and murine pulmonary adenomas: a preliminary report. Nutr Cancer 1981; 3:72-74.
45. Dahl AR, Grossi IM, Houchens DP, et al. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res 2000; 6:3015-3024.
46. Kisley LR, Barrett BS, Dwyer-Nield LD, et al. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 2002; 23:1653-1660.
47. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1:11-21.
48. Mann JR, DuBois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004; 10:145-152. This recent review notes that COX-2-specific agents have promise in the chemoprevention of gastrointestinal tumors.
49. Kurie JM, DuBois RN. Prostaglandin E synthase: another enzyme in the cyclooxygenase pathway driving epithelial cancer? Clin Cancer Res 2001; 7:2608-2610.
50. Bunn PA Jr, Keith RL. The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer. Clin Lung Cancer 2002; 3:271-277.
51. Schneider MR, Tang DG, Schirner M, et al. Prostacyclin and its analogues: antimetastatic effects and mechanisms of action. Cancer Metastasis Rev 1994; 13:349-364.
52. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306:1954-1957. Some of the negative cardiovascular side effects of COX inhibitors may be avoided with supplementation with prostacyclin analogs.
53. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002; 62:734-740.
54. Keith RL, Miller YE, Hudish TM, et al. Pulmonary prostacyclin synthase over-expression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 2004; 64:5897-5904. The tobacco smoke model is a difficult one in which to demonstrate chemoprevention, but has obvious clinical relevance.
55. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029-1035. [See comments.]
56. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-1149.
57. Omenn GS. Chemoprevention of lung cancer: the rise and demise of beta-carotene. Annu Rev Public Health 1998; 19:73-99.
58. Vainio H. Chemoprevention of cancer: lessons to be learned from beta-carotene trials. Toxicol Lett 2000; 112-113:513-517.
59. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000; 6:2973-2979.
60. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12:937-945.
61. Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer 1992; 65:737-743.
62. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase lib trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002; 94:1001-1009.
63. Lam S, leRiche JC, McWilliams A, et al. A randomized phase lib trial of Pulmicort Turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004; 10:6502-6511. Although budesonide is effective in the murine model of adenocarcinoma, it was not effective in reversing dysplasia of the central airways. Interestingly, peripheral nodules on CT scan resolved more commonly in the budesonide group; however, the histology of these was not assessed.
64. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-440.
65. Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 93:1385-1391.
66. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
67. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605-618.
68. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 11:1216-1222.
69. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92:977-986.
70. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 2001; 61:1457-1463.
71. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001; 93:605-618.